share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zaderej Karen L.

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zaderej Karen L.

EyePoint Pharmaceuticals | 4：持股变动声明-董事 Zaderej Karen L.
美股sec公告 ·  07/12 17:04
Moomoo AI 已提取核心信息
On July 11, 2024, Karen L. Zaderej, associated with EyePoint Pharmaceuticals, Inc. (EYPT), completed a transaction to acquire 2,000 shares of the company's common stock at no cost. This transaction was categorized as an exercise or conversion of derivative security, which is typically related to options or warrants being converted into stock. Following this acquisition, Zaderej's direct holdings in EyePoint Pharmaceuticals increased to a total of 4,000 shares of common stock.
On July 11, 2024, Karen L. Zaderej, associated with EyePoint Pharmaceuticals, Inc. (EYPT), completed a transaction to acquire 2,000 shares of the company's common stock at no cost. This transaction was categorized as an exercise or conversion of derivative security, which is typically related to options or warrants being converted into stock. Following this acquisition, Zaderej's direct holdings in EyePoint Pharmaceuticals increased to a total of 4,000 shares of common stock.
2024年7月11日，与eyepoint pharmaceuticals有关的Karen L. Zaderej以零成本完成了一笔交易，以获取该公司普通股2000股。此项交易被归类为衍生证券的行权或转换，通常是指期权或认股权转换为股票。此次收购后，Zaderej在EyePoint Pharmaceuticals的直接持股总数增加到了4000股。
2024年7月11日，与eyepoint pharmaceuticals有关的Karen L. Zaderej以零成本完成了一笔交易，以获取该公司普通股2000股。此项交易被归类为衍生证券的行权或转换，通常是指期权或认股权转换为股票。此次收购后，Zaderej在EyePoint Pharmaceuticals的直接持股总数增加到了4000股。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息